How could cellular therapies and cancer vaccines transform the future of treatment for ALK-positive lung cancer? Host Dr. Narjust Florez sits down with Dr. Vincent Lam and Dr. Carmen Mecca to explore the latest research, the science driving these innovative approaches, and what these advances could mean for patients and the future of precision oncology.
Key Topics Covered:
•	ALK-positive lung cancer
•	Cellular Therapy
•	Vaccines

Guests:

Vincent Lam, MD
Associate Professor of Oncology, Johns Hopkins University School of Medicine
Director, Thoracic Oncology Clinical Research Program
Sidney Kimmel Comprehensive Cancer Center


Carmen Mecca. PhD
Postdoctoral Fellow, Chiarle Lab
Department of Pathology
Boston Children’s Hospital

FDA Approval: Zidesamtinib and ROS1 NSCLC

Dr. Stephen Liu and Dr. Narjust Florez host Lung Cancer Considered, the podcast of The International Association for the Study of Lung Cancer (IASLC). IASLC is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 11,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

Lung Cancer considered is funded in part by Current sponsors: 
•	AbbVie 
•	AstraZeneca
•	Gilead
•	J&J
•	Summit